Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA.
Curr Osteoporos Rep. 2024 Dec;22(6):553-560. doi: 10.1007/s11914-024-00887-x. Epub 2024 Sep 14.
In this review, we outline the different etiologies of osteoporosis in the oncologic setting and describe the basis for using PET/CT as screening tool for osteoporosis with a focus on the radiotracers [F]FDG and [F]NaF.
Osteoporosis is a condition commonly affecting cancer patients due to their age, cancer-specific treatment agents, and effects of cancer. In terms of the unifying mechanism, decreased ratio of osteoblast-bone formation to osteoclast-bone resorption is responsible for causing osteoporosis. PET/CT, a crucial metabolic imaging modality in the oncologic imaging, could be a useful tool for the opportunistic screening of osteoporosis. There are two approaches with which osteoporosis could be identified with PET/CT-using either the (1) CT- based or (2) PET- based approaches. While the CT-based approach has been used with [F]FDG PET/CT, both CT- and PET-based approaches can be employed with [F]NaF-PET/CT as [F]NaF is a radiotracer specific for osteoblast activity.
在这篇综述中,我们概述了肿瘤环境中骨质疏松症的不同病因,并描述了使用 PET/CT 作为骨质疏松症筛查工具的基础,重点介绍了放射性示踪剂 [F]FDG 和 [F]NaF。
由于年龄、癌症特异性治疗药物以及癌症的影响,骨质疏松症是一种常见于癌症患者的疾病。就统一机制而言,成骨细胞-骨形成与破骨细胞-骨吸收的比例降低是导致骨质疏松症的原因。PET/CT 是肿瘤影像学中一种重要的代谢成像方式,可作为骨质疏松症的一种有用的筛查工具。有两种方法可以用 PET/CT 来识别骨质疏松症——(1)基于 CT 的方法,或(2)基于 PET 的方法。虽然 CT 基方法已用于 [F]FDG PET/CT,但都可以采用 CT-和 PET-基于方法用 [F]NaF-PET/CT,因为 [F]NaF 是一种专门针对成骨细胞活性的放射性示踪剂。